F Stephen Hodi Selected Research

Hypophysitis

1/2022	Multiple high-grade and rare immune-related adverse events in a colon cancer patient with genomic and cytokine profiling.
12/2021	Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study.
1/2019	Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.
2/2018	Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
11/2016	Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

F Stephen Hodi Research Topics

Disease

198	Melanoma (Melanoma, Malignant) 04/2024 - 05/2002
195	Neoplasms (Cancer) 05/2024 - 05/2002
23	Disease Progression 12/2023 - 05/2012
22	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 05/2002
21	Neoplasm Metastasis (Metastasis) 01/2022 - 05/2002
14	Renal Cell Carcinoma (Grawitz Tumor) 01/2021 - 03/2013
12	Pneumonia (Pneumonitis) 01/2022 - 07/2015
12	Brain Neoplasms (Brain Tumor) 12/2021 - 05/2012
11	Colitis 01/2023 - 08/2015
9	Fatigue 12/2023 - 05/2012
9	Body Weight (Weight, Body) 10/2019 - 08/2010
8	Uveal melanoma 04/2024 - 01/2012
7	Lung Neoplasms (Lung Cancer) 12/2016 - 03/2003
6	Exanthema (Rash) 04/2024 - 05/2012
6	Leukemia 01/2023 - 01/2006
5	Inflammation (Inflammations) 01/2023 - 03/2013
5	Hypophysitis 01/2022 - 11/2016
5	Hypothyroidism 01/2019 - 01/2014
4	Hepatitis 02/2024 - 12/2020
4	Fever (Fevers) 12/2023 - 02/2015
4	Diarrhea 12/2023 - 01/2017
4	Necrosis 01/2023 - 04/2003
4	Carcinoma (Carcinomatosis) 01/2021 - 04/2003
4	Lymphoma (Lymphomas) 01/2018 - 09/2002
3	Hyponatremia 04/2024 - 08/2015
3	Graft vs Host Disease (Graft-Versus-Host Disease) 12/2022 - 07/2016
3	Triple Negative Breast Neoplasms 01/2022 - 01/2020
3	Adenocarcinoma of Lung 01/2021 - 08/2015
3	Ovarian Neoplasms (Ovarian Cancer) 11/2020 - 03/2003
3	Autoimmune Diseases (Autoimmune Disease) 02/2018 - 01/2006
3	Testicular Neoplasms (Testicular Cancer) 01/2016 - 05/2012
2	Pruritus (Itching) 04/2024 - 12/2023
2	Anemia 04/2024 - 12/2023
2	Nausea 12/2023 - 01/2017
2	Pancreatitis 03/2023 - 01/2023
2	Abdominal Pain (Pain, Abdominal) 01/2023 - 01/2022
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2023 - 11/2021
2	Enterocolitis 01/2023 - 01/2020
2	Breast Neoplasms (Breast Cancer) 12/2022 - 04/2008

Drug/Important Bio-Agent (IBA)

87	IpilimumabIBA 01/2023 - 09/2008
84	Immune Checkpoint InhibitorsIBA 02/2024 - 03/2013
47	NivolumabIBA 02/2023 - 04/2014
32	pembrolizumabIBA 03/2024 - 07/2013
23	AntigensIBA 01/2023 - 05/2002
20	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 12/2022 - 05/2002
19	Proteins (Proteins, Gene)FDA Link 11/2023 - 03/2003
19	AntibodiesIBA 10/2023 - 05/2002
19	Monoclonal AntibodiesIBA 10/2019 - 09/2007
17	LigandsIBA 11/2023 - 06/2006
16	VaccinesIBA 12/2022 - 05/2002
16	Biomarkers (Surrogate Marker)IBA 10/2022 - 04/2008
15	B7-H1 AntigenIBA 05/2024 - 11/2014
15	CytokinesIBA 01/2022 - 12/2010
14	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022 - 05/2010
12	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2024 - 12/2010
12	atezolizumabIBA 11/2023 - 07/2014
11	CTLA-4 AntigenIBA 10/2020 - 04/2003
10	Bevacizumab (Avastin)FDA Link 06/2021 - 01/2014
10	VemurafenibIBA 01/2019 - 01/2012
8	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022 - 04/2016
8	Programmed Cell Death 1 ReceptorIBA 01/2019 - 03/2013
7	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2016
7	Imatinib Mesylate (Gleevec)FDA Link 05/2015 - 04/2008
6	InterferonsIBA 01/2023 - 01/2018
6	trametinibIBA 01/2019 - 03/2013
6	dabrafenibIBA 01/2019 - 03/2013
5	SteroidsIBA 03/2023 - 01/2017
5	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 01/2019
5	Neoplasm Antigens (Tumor Antigens)IBA 12/2022 - 03/2003
5	Interleukin-2 (IL2)IBA 10/2014 - 01/2006
4	Alanine Transaminase (SGPT)IBA 01/2023 - 04/2015
4	Protein Kinase CIBA 01/2022 - 01/2012
4	PlatinumIBA 01/2021 - 06/2002
4	Complementary DNA (cDNA)IBA 06/2008 - 05/2002
3	Lipase (Acid Lipase)FDA Link 01/2023 - 04/2015
3	sotrastaurinIBA 01/2022 - 09/2012
3	SurvivinIBA 08/2019 - 09/2012
3	EpitopesIBA 08/2019 - 11/2005
3	Insulin (Novolin)FDA Link 01/2019 - 04/2012
3	Immune Checkpoint ProteinsIBA 03/2018 - 02/2016
3	talimogene laherparepvecIBA 09/2017 - 01/2015
3	SuspensionsIBA 12/2016 - 02/2003
3	Glycoproteins (Glycoprotein)IBA 11/2016 - 08/2010
3	Codon (Codons)IBA 09/2012 - 01/2012
2	itacitinibIBA 03/2024 - 12/2023
2	parsaclisibIBA 03/2024 - 12/2023
2	Circulating Tumor DNAIBA 11/2023 - 01/2022
2	Interferon alpha-2 (Roferon-A)FDA Link 01/2023 - 01/2020
2	Granzymes (Granzyme)IBA 01/2023 - 10/2021
2	GlucocorticoidsIBA 01/2023 - 01/2016
2	relatlimabIBA 12/2022 - 01/2022
2	Membrane Proteins (Integral Membrane Proteins)IBA 12/2022 - 04/2016

Therapy/Procedure

132	Therapeutics 04/2024 - 01/2006
66	Immunotherapy 11/2023 - 01/2006
12	Drug Therapy (Chemotherapy) 12/2022 - 06/2002
11	Radiotherapy 01/2022 - 01/2014
6	Aftercare (After-Treatment) 02/2023 - 04/2014
3	Hematopoietic Stem Cell Transplantation 01/2023 - 07/2016
3	Retreatment 12/2016 - 04/2013
2	Precision Medicine 10/2022 - 01/2017